Database Query Results : Urolithin, ,

Uro, Urolithin: Click to Expand ⟱
Features:
Urolithins are gut microbiota–derived dibenzopyran-6-one metabolites formed from ellagitannins → ellagic acid. They are the bioactive, systemically relevant forms responsible for most of the anticancer, mitochondrial, and signaling effects attributed to pomegranate and berry consumption.
Ellagic acid itself is largely confined to the gut lumen; urolithins are what reach circulation and tissues.

Urolithin A (UA), Most studied; mitophagy, anticancer, anti-inflammatory
Humans fall into urolithin metabotypes:
Metabotype	Description	            Approx. Population
A	        Produces UA (best profile)	~40%
B	        Produces UB ± UA	       ~25–30%
0	        Non-producer	                ~30%

ROS Modulation (Context-Dependent)
Cancer cells:
-Mild ROS ↑ or redox stress → apoptosis, growth arrest
Normal cells:
-ROS ↓, improved mitochondrial efficiency

This duality is why urolithins are less chemo-antagonistic than classic antioxidants.

Anticancer Signaling
↓ PI3K/AKT/mTOR
↓ Wnt/β-catenin
↓ NF-κB, STAT3
Cell-cycle arrest (G1/S)

Unlike sulforaphane or NAC, urolithins:
-Do not strongly upregulate NRF2 in cancer cells
-May normalize NRF2 signaling in normal cells
Direct Urolithin A Supplements: Bypass microbiome dependency
Scientific Papers found: Click to Expand⟱
4870- Uro,    Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
- in-vivo, AD, NA
*cognitive↑, *Apoptosis↓, *neuroP↑, *Aβ↓, *AMPK↑, *NF-kB↓, *MAPK↓, *BACE↑, *neuroG↑, *Inflam↓, *memory↑,
4858- Uro,    The Metabolite Urolithin-A Ameliorates Oxidative Stress in Neuro-2a Cells, Becoming a Potential Neuroprotective Agent
- in-vitro, Nor, NA
*ROS?, *neuroP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSR↑, *monoA↓, *tyrosinase↓,
4859- Uro,  Rad,    Urolithin A Enhances Tight Junction Protein Expression in Endothelial Cells Cultured In Vitro via Pink1-Parkin-Mediated Mitophagy in Irradiated Astrocytes
- in-vitro, Nor, NA
*ROS↓, *VEGF↓,
4860- Uro,    Urolithins–gut Microbial Metabolites with Potential Health Benefits
- Review, Nor, NA - Review, AD, NA - Review, Park, NA
*ROS↓, *Inflam↓, TumCG↓, *neuroP↑, *cardioP↑, *LDL↓, *BioAv↝, *BioAv↓, *BioAv↑, *SIRT1↑, *mTOR↑, *BDNF↑, *cognitive↑,
4861- Uro,    Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions
- in-vivo, AD, NA
*memory↑, *Aβ↓, *toxicity↓, *BBB↑, *p‑tau↓, *eff↓, *IL1α↓, *MCP1↓, *MIP‑1α↓, *TNF-α↓, *IL2↓, *SIRT1↓, *DNAdam↓, *Dose↝, *Strength↑, *motorD↑, *CTSZ↓,
4862- Uro,    Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease
- in-vivo, AD, NA - in-vitro, Nor, PC12
*cognitive↑, *p‑PI3K↓, *p‑Akt↓, *AMPK↑, *VDAC1↓, *neuroP↑, *PARK2↑, *PTEN↑, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p62↓, *Aβ↓, *Apoptosis↓,
4863- Uro,    Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer's disease
- in-vivo, AD, NA
*memory↑, *Aβ↓, *OS↑, *cognitive↑,
4864- Uro,    Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease
- Review, AD, NA
*neuroP↑, *Half-Life↝, *BBB↑, *toxicity↓, *Inflam↓, *Strength↑, *BACE↓, *Aβ↓, *MitoP↑, *SIRT1↑, *SIRT3↑, *AMPK↑, *PGC-1α↑, *mTOR↓, *PARK2↑, *Beclin-1↑, *ROS↓, *GutMicro↑, *Risk↓,
4865- Uro,    Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis
- in-vitro, Diabetic, NA - in-vitro, AD, NA
*antiOx↑, *neuroP↑, *Ca+2↓, *Aβ↓, *BACE↓, *p‑tau↓, *cognitive↑,
4867- Uro,    Urolithin A exhibits a neuroprotective effect against Alzheimer’s disease by inhibiting DYRK1A activity
- in-vivo, AD, NA - in-vitro, AD, HEK293
*neuroP↑, *DYRK1A↓, *memory↑, *p‑tau↓, *Inflam↓,
4868- Uro,    Urolithin A improves Alzheimer’s disease cognition and restores mitophagy and lysosomal functions
- in-vivo, AD, NA
*memory↑, *Aβ↓, *tau↓, *MitoP↑, *lysosome↑, *CTSZ↝,
4869- Uro,    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*MitoP↑, *Inflam↓, *antiOx↑, *Risk↓, *Aβ↓, *p‑tau↓, *p62↓, *PARK2↑, *MMP↑, *ROS↓, *Strength↑, *CRP↓, *IL1β↓, *IL6↓, *TNF-α↓, *AMPK↑, *NF-kB↓, *MAPK↓, *p62↑, *NRF2↑, *SOD↑, *Catalase↑, *HO-1↑, *Ferroptosis↓, *lipid-P↓, *Cartilage↑, *PI3K↓, *Akt↓, *mTOR↓, *Apoptosis↓, *neuroP↑, *Bcl-2↓, *BAX↑, *Casp3↑, *ATP↑, *eff↑, *motorD↑, *NLRP3↓, *radioP↑, *BBB↑,
4857- Uro,    Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study
- in-vitro, ESCC, KYSE-30
tumCV↓, selectivity↑, TumCCA↑, ROS↑, Bcl-2↓, BAX↑, P21↑, MMP2↓, MMP9↓,
4871- Uro,  DHA,  LT,    A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease
- in-vitro, AD, NA
*ATP↑, *Apoptosis↓,
4872- Uro,    Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity
- in-vitro, AD, HEK293
*DYRK1A↓, *antiOx↑, *Inflam↓, *neuroP↑, *memory↑, *p‑tau↓, *Aβ↓, *neuroP↑,
4873- Uro,    Urolithin A Inhibits Anterior Basolateral Amygdala to Ventral Hippocampal CA1 Circuit to Ameliorate Amyloid-β-Impaired Social Ability
- in-vivo, AD, NA
*Aβ↓, *cognitive↑,
4874- Uro,  EGCG,    A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease
- in-vivo, AD, NA
*motorD↑, *memory↑, *MitoP↑, *Aβ↓, *mitResp↑, *Nrf1↑, *PINK1↑, *PARK2↑, *ATG5↑, *Bcl-2↑, *H2O2↓, *ROS↓, *lipid-P↓, *mt-ATP↑,
4875- Uro,    Impact of the Natural Compound Urolithin A on Health, Disease, and Aging
- Review, AD, NA - Review, Stroke, NA - Review, ostP, NA - Review, IBD, NA
*MitoP↓, *Strength↑, *PINK1↑, *PARK2↑, *Inflam↓, *COX2↓, *IL1β↓, *IL6↓, *TNF-α↓, *OS↑, *cardioP↑, *memory↑, *neuroG↑, *neuroP↑, *Cartilage↑, *Inflam↓, *RenoP↑, *eff↑, *Dose↝, *Half-Life↑, *NRF2↑, *GutMicro↑,
4876- Uro,    Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management
- Review, Park, NA - Review, AD, NA
*Inflam↓, *antiOx↓, *neuroP↑, *p‑tau↓, *Aβ↓, *eff↑, *BioAv↓, *BioAv↑, *GSH↑, *SOD↑, *lipid-P↓, *Catalase↑, *GSR↑, *GPx↑, *ROS↓, *NRF2↑, *GutMicro↑, *Risk↓, *BBB↓, *NLRP3↓, *MAOA↓,
4877- Uro,    Urolithin-A Derivative UAS03 Improves Cognitive Deficits and Memory by Activating Nrf2 Pathways to Alleviate Oxidative Stress and Neuroinflammation
- in-vivo, AD, NA
*cognitive↑, *memory↑, *neuroP↑, *NRF2↑, *ROS↓, *Inflam↓, *IL1β↓, *TNF-α↓, *COX2↓,
4878- Uro,    Activation of the Gut–Brain Interaction by Urolithin A and Its Molecular Basis
- Review, AD, NA
*memory↑, *SIRT1↑, *cognitive↑, *BDNF↑, *Apoptosis↓, *neuroG↑,
4879- Uro,    Neuroprotective Effect of Urolithin A against Cerebellum Changes in Streptozotocin-Induced Alzheimer’s Disease Rat Model
- in-vitro, AD, NA
*neuroP↑,
4880- Uro,    Urolithins: A Prospective Alternative against Brain Aging
- Review, AD, NA
*cognitive↑, *memory↑, *antiOx↑, *BBB↑, *ROS↓, *lipid-P↓, *Catalase↑, *SOD↑, *GSR↑, *GPx↑, *CREB↑, *BDNF↑, *neuroP↑, *Inflam↓, *MitoP↑, *Aβ↓, *tau↓, *NLRP3↓, *SIRT1↑, *SIRT3↑,
4884- Uro,    A review of pomegranate supplementation: A promising remedial avenue for Alzheimer's disease
- Review, AD, NA
*antiOx↑, *neuroG↑, *Inflam↓, *cognitive↑,
4845- Uro,    The gut microbiota metabolite urolithin A, but not other relevant urolithins, induces p53-dependent cellular senescence in human colon cancer cells
- in-vitro, Colon, HCT116
TumCCA↑, P53↑, P21↑,
4834- Uro,    Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer
- Human, Pca, NA
eff↑, NK cell↑,
4835- Uro,    Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway
- in-vitro, SCC, NA
TumCD↑, ER Stress↑, Akt↓, mtDam↓, p‑mTOR↓, *BioAv↝, ROS↑, TumCCA↑, Apoptosis↑, ERK↓,
4836- Uro,    Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation
- in-vitro, Var, NA
FOXO1↑, TumCG↓, PD-1↓, TIM-3↓,
4837- Uro,    Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review
- Review, Var, NA
AntiCan↑, TumCCA↑, Apoptosis↑, TumAuto↑, *BioAv↝, *BioAv↑, RAS↓, ERK↓, AR↓, TumCP↓, PI3K↓, Akt↓, NF-kB↓, COX2↓, IL6↓, IL1β↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, P53↑, Casp3↑, PARP↑, ROS↓, toxicity↓,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,
4839- Uro,    Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
tumCV↓, Apoptosis↓, P53↑, P21↑, PUMA↑, NOXA↑, MDM2↓, XIAP↓,
4840- Uro,    Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer
- vitro+vivo, BC, NA
MMP↓, TumCP↓, Apoptosis↑, tumCV↓, ER-α36↝, *toxicity↓,
4841- Uro,    Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells
- in-vitro, CRC, HT29 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
TumCP↓, TumCCA↑, Apoptosis↑, P53↑, P21↑, Bcl-2↓, Cyt‑c↑, Casp↑, ROS↑, *ROS↓,
4842- Uro,    Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, MCF-7 - in-vitro, BC, 4T1
Inflam↓, IL6↓, TNF-α↓, eff↑, STAT3↓, TumCP↓, TumCMig↓,
4843- Uro,    The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide
- in-vitro, Pca, LNCaP
TumCP↓, eff↑, ChemoSen↝,
4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, TumCI↓, EMT↓, Snail↓, MDM2↑, P53↑, E-cadherin↑, N-cadherin↓, Vim↓,
4833- Uro,    Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
BioAv↝, TumAuto↝, TumCG↓, TumMeta↓, ChemoSen↑, Imm↑, RadioS↑, BioAv↑, other↝, eff↓, *antiOx↓, *Inflam↓, AntiCan↓, AntiAge↑, chemoP↑, *neuroP↑, *ROS↓, *cognitive↑, *lipid-P↓, *cardioP↑, *TNF-α↓, *IL6↓, GutMicro↑, TumCCA↑, Apoptosis↑, angioG↓, NF-kB↓, PI3K↓, Akt↓, Casp↑, survivin↓, TumCP↓, cycD1/CCND1↓, cMyc↑, BAX↑, Bcl-2↓, COX2↓, P53↑, p38↑, *ROS↓, *SOD↑, *GPx↑, SIRT1↑, FOXO1↑, eff↑, ChemoSen↑,
4846- Uro,    Urolithin A exerts anti-tumor effects on gastric cancer via activating autophagy-Hippo axis and modulating the gut microbiota
- in-vivo, GC, NA
TumCG↓, Hippo↑, Warburg↓, Apoptosis↑, GutMicro↑,
4847- Uro,    Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells
- in-vitro, CRC, SW-620
TumCP↓, TumCMig↓, MMP9↓, TumAuto↑, Apoptosis↑, TumCCA↓, TumMeta↓, ChemoSen↓,
4848- Uro,  OXA,    Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells
- in-vitro, Colon, HCT116
TumCG↓, ChemoSen↑, P53↝, P21↑,
4849- Uro,    Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway
- vitro+vivo, GC, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, TumAuto↑, TumCG↓, chemoP↑, ChemoSen↑,
4850- Uro,    Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population
- Review, Var, NA
*BioAv↑, BioAv↑,
4851- Uro,    Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1
- in-vitro, OS, MG63
TumCMig↓, TumCI↓, TumCA↑, MMP2?, MMP9?,
4852- Uro,    Dietary Urolithin B Suppresses Lung Tumorigenesis Correlating with Autophagy Induction and Gut Microbiota Remodeling
- vitro+vivo, Lung, NA
TumCG↓, *GutMicro↑, *Inflam↓, *antiOx↑, AntiTum↑, TumCCA↑, Apoptosis↑,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
4854- Uro,    Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)
- Review, Pca, NA
AR↓, ROS↓, Apoptosis↑, selectivity↑, Dose↑, MDA↓, SOD↑, GPx↑, ROS↑, Casp3↑, Casp9↑,
4855- Uro,    Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells
- in-vitro, Bladder, UMUC3
TumCCA↑, PI3K↓, Akt↓, MAPK↓,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 48

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GPx↑, 1,   MDA↓, 1,   ROS↓, 2,   ROS↑, 5,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 2,   mtDam↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   cMyc↑, 1,   SIRT1↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 2,   Apoptosis↓, 1,   Apoptosis↑, 12,   BAX↑, 3,   Bcl-2↓, 3,   Casp↑, 2,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Hippo↑, 1,   MAPK↓, 1,   MDM2↓, 1,   MDM2↑, 2,   NOXA↑, 1,   p38↑, 1,   PUMA↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 3,   TumAuto↝, 1,  

DNA Damage & Repair ⓘ

P53↑, 6,   P53↝, 1,   p53 Wildtype↑, 1,   PARP↑, 2,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 5,   TumCCA↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 3,   ERK↓, 2,   FOXO1↑, 2,   IGF-1↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   PI3K↓, 4,   RAS↓, 1,   STAT3↓, 1,   TumCG↓, 8,   Wnt↓, 2,  

Migration ⓘ

E-cadherin↑, 3,   ER-α36↝, 1,   MMP2?, 1,   MMP2↓, 2,   MMP9?, 1,   MMP9↓, 3,   N-cadherin↓, 3,   Snail↓, 3,   Treg lymp↓, 1,   TumCA↑, 1,   TumCI↓, 4,   TumCMig↓, 7,   TumCP↓, 10,   TumMeta↓, 2,   Vim↓, 3,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   TAMS↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1β↓, 2,   IL6↓, 3,   Imm↑, 1,   Inflam↓, 2,   NF-kB↓, 3,   NK cell↑, 1,   PD-1↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

TIM-3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 3,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 4,   ChemoSen↝, 1,   Dose↑, 1,   eff↓, 2,   eff↑, 4,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 2,   GutMicro↑, 2,   IL6↓, 3,   NOS2↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiCan↓, 1,   AntiCan↑, 1,   AntiTum↑, 1,   chemoP↑, 2,   OS↑, 1,   toxicity↓, 1,  
Total Targets: 108

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 2,   antiOx↑, 6,   Catalase↑, 4,   Ferroptosis↓, 1,   GPx↑, 4,   GSH↑, 1,   GSR↑, 3,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 6,   Nrf1↑, 1,   NRF2↑, 4,   PARK2↑, 5,   ROS?, 1,   ROS↓, 11,   SIRT3↑, 2,   SOD↑, 5,   VDAC1↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 2,   mt-ATP↑, 1,   mitResp↑, 1,   MMP↑, 1,   PGC-1α↑, 1,   PINK1↑, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 4,   CREB↑, 1,   LDL↓, 1,   SIRT1↓, 1,   SIRT1↑, 4,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↓, 5,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-2↑, 1,   Casp3↑, 1,   Ferroptosis↓, 1,   MAPK↓, 2,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   DYRK1A↓, 2,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   lysosome↑, 1,   MitoP↓, 1,   MitoP↑, 5,   p62↓, 2,   p62↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 2,   mTOR↑, 1,   neuroG↑, 4,   PI3K↓, 1,   p‑PI3K↓, 1,   PTEN↑, 1,   tyrosinase↓, 1,  

Migration ⓘ

Ca+2↓, 1,   Cartilage↑, 2,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Barriers & Transport ⓘ

BBB↓, 1,   BBB↑, 4,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CRP↓, 1,   CTSZ↓, 1,   CTSZ↝, 1,   IL1α↓, 1,   IL1β↓, 3,   IL2↓, 1,   IL6↓, 3,   Inflam↓, 14,   MCP1↓, 1,   MIP‑1α↓, 1,   NF-kB↓, 2,   TNF-α↓, 5,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 3,   MAOA↓, 1,   monoA↓, 1,   tau↓, 2,   p‑tau↓, 6,  

Protein Aggregation ⓘ

Aβ↓, 13,   BACE↓, 2,   BACE↑, 1,   NLRP3↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 5,   BioAv↝, 3,   Dose↝, 2,   eff↓, 1,   eff↑, 3,   Half-Life↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   GutMicro↑, 4,   IL6↓, 3,  

Functional Outcomes ⓘ

cardioP↑, 3,   cognitive↑, 11,   memory↑, 11,   motorD↑, 3,   neuroP↑, 16,   OS↑, 2,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 3,   Strength↑, 4,   toxicity↓, 4,  
Total Targets: 104

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:383  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page